OracleBio will be attending the 4th Annual Advances in Immuno-oncology Congress 2019, which takes place from the 20th to 21st of May 2019 in London, UK.
OracleBio will be exhibiting at Booth 23 throughout the congress.
OracleBio offers a range of digital pathology services to support pre-clinical and clinical oncology R&D. Using immunohistochemistry and immunoflourescence techniques, we are able to produce a variety of quantifiable results valuable to oncology research, such as immune cell number, immune cell co-localisation and spatial distribution within the tumor microenvironment. Click here to find out more information about how our services can support your oncology research.
The 4th Annual Advances in Immuno-oncology Congress covers immuno-oncology drug development from early discovery through to the clinic, featuring key therapeutic strategies such as T-cell therapy, bispecific drug discovery, oncolytic viral therapies and cancer vaccines. In addition, the congress will shed light on technological innovation from single cell analysis tools and NGS approaches to biomarker technologies like mass spectrometry, immunohistochemistry and Cytof. To find out more about the 4th Annual Advances in Immuno-oncology Congress 2019, please click here.
Hannah Thomson, OracleBio’s Business Development Manager, along with our Business Development Assistant, Alison Stewart, will be at Booth 23 throughout the meeting. If you would like to learn more about OracleBio’s services please contact us.
To keep up to date with all OracleBio news and events, follow us on LinkedIn by clicking the button below: